1,104 results on '"Cui, Jiuwei"'
Search Results
2. Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
3. Efficacy, metabolic characteristics, safety and immunogenicity of AK-HER2 compared with reference trastuzumab in patients with metastatic HER2-positive breast cancer: a multicenter, randomized, double-blind phase Ⅲ equivalence trial
4. Profiling mitochondria-polyribosome lncRNAs associated with pluripotency
5. Prognostic value of the combined effect of nutritional status and body water component in patients with colorectal cancer
6. Current landscape and challenges ahead of immuno-molecular mechanism and immunotherapy strategy of brain metastases
7. Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial
8. Meloxicam inhibits STING phosphorylation and alleviates intracellular DNA-mediated autoimmune responses
9. BAX as the mediator of C-MYC sensitizes acute lymphoblastic leukemia to TLR9 agonists
10. Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
11. Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer
12. Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE)
13. Reciprocal costimulatory molecules control the activation of mucosal type 3 innate lymphoid cells during engagement with B cells
14. Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC
15. Association Between Cardiovascular Health and Retinopathy in US Adults: From NHANES 2005-2008
16. Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial
17. First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial
18. Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial
19. Vitamin B6 Turnover Predicts Long-term Mortality Risk in Patients with Type 2 Diabetes
20. Association between ICW/TBW ratio and cancer prognosis: Subanalysis of a population-based retrospective multicenter study
21. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations: A Phase 1 Trial
22. Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study
23. Publisher Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC
24. Targeting the lactic acid metabolic pathway for antitumor therapy
25. Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study
26. FLI-1-driven regulation of endothelial cells in human diseases
27. Association of Life’s Essential 8 with metabolic dysfunction-associated steatotic liver disease (MASLD), a cross-sectional study from the NHANES 2003–2018
28. CircARAP2 controls sMICA-induced NK cell desensitization by erasing CTCF/PRC2-induced suppression in early endosome marker RAB5A
29. Association of volatile organic compound levels with chronic obstructive pulmonary diseases in NHANES 2013–2016
30. Development and validation of an inflammatory biomarkers model to predict gastric cancer prognosis: a multi-center cohort study in China
31. CT-based muscle and adipose measurements predict prognosis in patients with digestive system malignancy
32. Profiling the role of m6A effectors in the regulation of pluripotent reprogramming
33. Therapeutic potential of engineering the mitochondrial genome
34. Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
35. Association Between Visceral Fat Area and Cancer Prognosis: A Population-Based Multicenter Prospective Study
36. Efficacy and safety of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with solid tumors: Clinical data from advanced cervical cancer and platinum-resistant recurrent ovarian cancer cohorts.
37. A phase II trial of anlotinib and fulvestrant in patients with HR-positive and HER2-negative, secondary aromatase inhibitor–resistant, metastatic breast cancer.
38. Natural killer cell therapy targeting cancer stem cells: Old wine in a new bottle
39. Immune checkpoint inhibitors as a threat to reproductive function: A systematic review
40. Therapeutic strategies targeting metabolic characteristics of cancer cells
41. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
42. Mitochondrial immune regulation and anti-tumor immunotherapy strategies targeting mitochondria
43. LncRNA Osilr9 coordinates promoter DNA demethylation and the intrachromosomal loop structure required for maintaining stem cell pluripotency
44. Comparison of the performance of the GLIM criteria, PG-SGA and mPG-SGA in diagnosing malnutrition and predicting survival among lung cancer patients: A multicenter study
45. Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial
46. Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial
47. Efficacy and Safety of Anti–Programmed Death-Ligand 1 Monoclonal Antibody Socazolimab With Carboplatin and Etoposide for Extensive-Stage SCLC: Results From the Phase 1b Clinical Trial
48. Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study
49. Title:Cross-sectional Examination of the Association Between Life's Essential 8 Score and Overactive Bladder——NHANES 2005-2018
50. Revisiting the mechanisms linking blood glucose to cognitive impairment: new evidence for the potential important role of klotho
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.